Close

Mr Daniel Tindanbil

EBOVAC Research Fellow

United Kingdom

A clinical research professional with over twenty years of experience in clinical research in many therapeutic areas including Malaria, Meningitis, Polio, Ebola virus disease, COVID_19 and Human papilloma virus ( HPV), the virus that causes cervical cancer. I have monitored and coordinated many clinical trials for CROs, research and academic institutions in many countries in Africa, including Ghana, Gambia, Tanzania, Gabon, Burkina Faso and Sierra Leone.

 

I monitored for  IQVIA (formerly Quintiles) from 2009 to 2013.  I conducted site assessments, site initiation, interim monitoring and close out visits on malaria vaccines trials in Burkina Faso, Gabon, Ghana and Tanzania.  I also monitored for PPD of Theormo Fisher Scientific from 2016 to 2018 also on malaria vaccine trials in Ghana and Burkina Faso. As a freelance, I monitored a polio vaccine trial at the MRC-Gambia unit for one year. I also did feasibility studies/site assessment for a global follicular lymphoma study in Ghana, Burkina Faso and Senegal for MCT, a CRO based in the middle East but now operating in West Africa.

 

I am well knowledgeable in regulatory and ethics committees’ requirements in Sub-Saharan Africa. I also have experience working with FDA inspectors. I helped to prepare the Mambolo site in Sierra Leone for a FDA inspection of the PREVAC/PREVAC-UP Ebola vaccine trial in Jan 2023. The site passed the inspection without any major findings.

 

I am currently the study manager of the GLOBE HPV study in Sierra Leone. The study aims to provide data on the burden of HPV among girls and women in South Asia and sub-Saharan Africa. Sierra Leone is one of the participating sites in Sub-Saharan Africa. I am also the trial manager of  a vaccine trial against HPV transmission. This vaccine trial seeks to assess the reduction of viral infectivity and potential transmission after one dose of a nonvalent HPV vaccine among HPV positive women between the ages 18-29 years in Sierra Leone.

 

As someone with experience in monitoring, coordinating and managing clinical trials  I am suitable for monitoring or clinical project management roles.

Affiliations

Department of Clinical Research
Faculty of Infectious and Tropical Diseases

Teaching

I have been supporting the CTM204 module; Regulatory Affairs, Good Clincal Practice (GCP) and Ethics for the last three years.

Research

Infectious diseases: Malaria, Ebola, HIV/TB and HepB. I also have interest in Oncology inclduing research on HPV, the virus that causes cervical cancer.

Selected Publications

Long-term safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen: a cohort study of previously vaccinated adults and children in Sierra Leone (the EBOVAC-Salone extension study)
Manno, D; Balami, AD; Bangura, A; Kamara, AB; Kallon, JA E; Conteh, M; Ayieko, P; Baiden, F; AFOLABI, MO; Faye, F; TINDANBIL, D; Foster, J; Owusu-Kyei, K; Kamara, MM; Koroma, B; Lawal, BJ; Otieno, GT; Jusu, MO; Njie, Y; Kowuor, D; Odeni, L; Fombah, AE; Morovia, FE; Bah, OM; Connor, NE; ... WATSON-JONES, D.
2026
The Lancet Regional Health - Africa
HPV infection among females aged 9-50 years in rural Sierra Leone: a cross-sectional survey from the GLOBE-HPV study
Faye, F; Samai, M; Lawal, B; Kallon, J; Folakemi, D; Campbell, A; TINDANBIL, D; Choi, E; Njie, Y; Ayieko, P; Hayes, R; BAISLEY, K; Kambale, K; Telele, N; Querec, T; Ahn, H; Lee, Y; Hill, A; Unger, E; Lynch, J; WATSON-JONES, D;
2025
37th Annual Conference of the International Papillomavirus Society
PREVAC Sierra Leone - Lessons Learned EDCTP
CHOI, E; TINDANBIL, D; Lawal, B; Bangura, M; Bangura, K; Kamara, M; Faye, F; Fleck, S; Whitworth, H; Lees, S; GREENWOOD, B; Samai, M; WATSON-JONES, D; Leigh, B;
2025
EDCTP Forum
Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.
Valayer, S; Alexandre, M; Prague, M; Beavogui, AH; Doumbia, S; Kieh, M; GREENWOOD, B; Leigh, B; Poupelin, M; Schwimmer, C; Sow, SO; Berry, IM; Kuhn, JH; Fusco, D; Cauwelaert, ND; Watson-Jones, D; Thiébaut, R; Lévy, Y; Yazdanpanah, Y; Richert, L; Lhomme, E; PREVAC study team,;
2024
Emerging microbes & infections
Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.
Wiedemann, A; Lhomme, E; Huchon, M; Foucat, E; Bérerd-Camara, M; Guillaumat, L; Yaradouno, M; Tambalou, J; Rodrigues, C; Ribeiro, A; Béavogui, AH; Lacabaratz, C; Thiébaut, R; Richert, L; Lévy, Y; Prevac study team,;
2024
Nature communications
Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the Congo.
Kavunga-Membo, H; WATSON-JONES, D; Kasonia, K; Edwards, T; Camacho, A; Mambula, G; Tetsa-Tata, D; Choi, EM-L; Aboubacar, S; Brindle, H; ROBERTS, C; Manno, D; Faguer, B; Mossoko, Z; Mukadi, P; Kakule, M; Balingene, B; Mapendo, EK; Makarimi, R; Toure, O; Campbell, P; Mousset, M; Nsaibirni, R; Ama, IS; Janvier, KK; ... Muyembe-Tamfum, JJ.
2024
Vaccines
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
CHOI, EM-L; Lacarra, B; AFOLABI, MO; Ale, BM; Baiden, F; Bétard, C; Foster, J; Hamzé, B; Schwimmer, C; Manno, D; D'Ortenzio, E; Ishola, D; Keita, CM; Keshinro, B; Njie, Y; Van Dijck, W; Gaddah, A; Anumendem, D; Lowe, B; Vatrinet, R; Lawal, BJ; Otieno, GT; Samai, M; Deen, GF; Swaray, IB; ... EBOVAC-3/EBL2005 Study Team,
2023
The Lancet Global health
Continuity and Rupture in Crisis: from Ebola to COVID-19 in Sierra Leone and the eastern Democratic Republic of the Congo.
James, M; MANSARAY, A; Thige, FO; Mafinda, M; Kasonia, KK; Paluku, JK; Timbo, AD; Karenzi, L; Ntabala, F; TINDANBIL, D; Leigh, B; Kavunga-Membo, H; WATSON-JONES, D; GALLAGHER, K; ENRIA, L;
2023
Global public health
The effect of malaria infection on the immune response to the two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in adults and children enrolled in a vaccine trial in Sierra Leone
MANNO, D; AYIEKO, P; Ishola, D; AFOLABI MBBS, MPH, PHD, FWACP, FHEA, FFPH, M; Baiden, F; TINDANBIL, D; Abu Bakarr, K; Bah, OM; Rogers, B; Owusu-Kyei, K; DRAMMEH, A; PATTERSON, C; Tetteh, K; KROMA, MT; Otieno, GT; Lawal, B; Gaddah, A; Deen, GF; Keshinro, B; Njie, Y; Kowuor, D; Lowe, B; Robinson, C; Leigh, B; DRAKELEY, C; ... WATSON-JONES, D.
2023
17TH VACCINE CONGRESS
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.
MANNO, D; PATTERSON, C; DRAMMEH, A; TETTEH, K; KROMA, MT; Otieno, GT; Lawal, BJ; SOREMEKUN, S; AYIEKO, P; Gaddah, A; Kamara, AB; Baiden, F; AFOLABI, MO; TINDANBIL, D; Owusu-Kyei, K; Ishola, D; Deen, GF; Keshinro, B; Njie, Y; Samai, M; Lowe, B; Robinson, C; Leigh, B; DRAKELEY, C; GREENWOOD, B; ... WATSON-JONES, D.
2023
Vaccines
See more information